IMS spin-off into Cognizant separate entity is awaiting board and IRS approvals.
Executive Summary
COGNIZANT (IMS) SPIN-OFF FROM D&B AWAITING FINAL APPROVAL by Dun & Bradstreet board and a ruling from the Internal Revenue Service regarding the tax-free treatment of the distribution. D&B unveiled plans at the beginning of this year to reconstitute itself as three independent entities: Cognizant Corp., Dun & Bradstreet Corp. and ACNielsen. The break-up was intended to be accomplished by mid-autumn; the current state of the deal indicates that it may have trouble meeting that objective.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth